Hot Features
プレミアム
Apogee Therapeutics Inc (APGE)
NASDAQ
登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subc... Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts. 詳細を表示
Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2H 2025 APG777 + APG333 can potentially address key drivers of respiratory diseases more broadly...
Positive interim Phase 1 data indicate APG808 was well-tolerated with half-life of approximately 55 days, supporting potential for 2- to 3- month dosing and demonstrating deep and sustained...
SAN FRANCISCO and WALTHAM, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for...
SAN FRANCISCO and WALTHAM, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for...
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -2.58 | -5.46610169492 | 47.2 | 48.26 | 43.26 | 253223 | 46.77952133 | CS |
| 4 | -1.13 | -2.46994535519 | 45.75 | 53.615 | 41.85 | 580814 | 47.32397725 | CS |
| 12 | -9.55 | -17.6296843271 | 54.17 | 63.5 | 41.85 | 459304 | 50.02497019 | CS |
| 26 | 5.32 | 13.5368956743 | 39.3 | 63.5 | 36.6 | 436317 | 49.35036902 | CS |
| 52 | 17.17 | 62.5500910747 | 27.45 | 72.29 | 27.05 | 494234 | 50.54672342 | CS |
| 156 | 23.12 | 107.534883721 | 21.5 | 72.29 | 14.19 | 441563 | 43.39735623 | CS |
| 260 | 23.12 | 107.534883721 | 21.5 | 72.29 | 14.19 | 441563 | 43.39735623 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
